1 Aim of the present study was to investigate the eects of norbormide, a selective vasoconstrictor agent of the rat peripheral vessels, on the whole-cell voltage-dependent L-type Ca 2+ current (I Ca(L) ) of freshly isolated smooth muscle cells from the rat caudal artery, using either the conventional or the amphotericin B-perforated whole-cell patch-clamp method. 2 Norbormide decreased L-type Ca 2+ current in a concentration-and voltage-dependent manner, without modifying the threshold and the maximum of the current-voltage relationship. Norbormideinduced I Ca(L) inhibition was reversible upon wash-out. 3 Norbormide both shifted the voltage dependence of the steady-state inactivation curve to more negative potentials by about 16 mV, without aecting the activation curve, and decreased the slope of inactivation. Norbormide, however, did not modify both the activation and the inactivation kinetics of the I Ca(L) . 4 Norbormide decreased I Ca(L) progressively during repetitive step depolarizations, with inhibition depending on the stimulation frequency (use-dependent block) as well as on the holding potential. 5 Addition of 50 mM norbormide caused the contraction of all freshly isolated cells and also of those impaled with the perforated method, but not of those impaled with the conventional method (i.e. dialysed). 6 In conclusion, these results prove norbormide to be a vascular L-type Ca 2+ channel inhibitor, which preferentially acts on the inactivated and/or open state of the channel. In rat caudal artery smooth muscle, however, this mechanism does not result in a vasodilating eect since it is overwhelmed by the mechanism underlying norbormide-induced vasoconstriction.
Introduction
Norbormide, 5-(a-hydroxy-a-2-pyridylbenzyl)-7-(a-2-pyridylbenzylidene)-5 norbormene-2,3-dicarboximide, is a synthetic compound introduced as a speci®c rat toxicant in 1964 (Roszkowski et al., 1964) . This compound is endowed with unique pharmacodynamic properties since it induces, at the same concentrations, selective contraction of rat peripheral arteries and relaxation of arteries of several non-rat species so far tested, as well as rat aorta (Roszkowski, 1965; Bova et al., 1996) . In the last years, several studies have been conducted in the attempt to identify the mechanisms underlying norbormide-induced vasoconstriction and vasorelaxation. Norbormide has been shown to elicit its selective vasoconstrictor eect by stimulating the phospholipase C (PLC)-protein kinase C (PKC) signalling cascade with promotion of Ca 2+ in¯ux mainly via verapamil-insensitive Ca 2+ channels (Bova et al., 2001a) . The mechanism(s) involved in norbormide-induced stimulation of PLC-PKC cascade is unknown; however, since this biochemical pathway is shared by most receptor-coupled vasoconstrictor agents, it has been hypothesized that norbormide selective vasoconstriction could be due to its interaction with a PLC-coupled receptor, uniquely expressed in the myocytes of rat terminal arteries (Bova et al., 2001a) .
The mechanism involved in norbormide-induced relaxation of rat aorta and non-rat arteries has not been elucidated. On the basis of indirect evidences, it was proposed that the drug could induce vasorelaxation by reducing Ca 2+ in¯ux through voltage-dependent Ca 2+ channels (Bova et al., 2001a) . Such evidences come from patch-clamp studies performed on guinea-pig ventricular myocytes, in which norbormide has been shown to reduce L-type Ca 2+ current (Bova et al., 1997) , and from experiments conducted on guinea-pig isolated hearts (Langendor preparation) in which it caused functional and electrocardiographic modi®cations similar to those induced by the Ca 2+ entry blocker verapamil (Bova et al., 1997) .
Albeit proposed as a safe compound to non-rat species (Roszkowski, 1965) , norbormide, orally administered to healthy volunteers, only reduces systolic blood pressure (Pelfrene, 2001 ). In view of its possible blocking activity on vascular L-type Ca 2+ channels, norbormide deserves further studies aimed at elucidating the mechanism of its myorelaxing eect. Consequently, this study investigated the electro-physiological eects of norbormide on voltage-dependent Ca 2+ channels in single myocytes freshly isolated from the rat caudal artery. The present results show indeed that norbormide reduces I Ca(L) , thus supporting the hypothesis that a block of L-type Ca 2+ channels may be involved in its vasorelaxant activity and introducing norbormide as a prototype of a novel chemical class of Ca 2+ antagonists.
Methods

Cell isolation procedure
Smooth muscle cells were freshly isolated from the tail main artery of male rats (350 ± 450 g) by means of collagenase treatment, as previously described (Fusi et al., 2001) . The cells were continuously superfused with physiological salt solution (PSS) using a peristaltic pump (LKB 2132) at a¯ow rate of 800 ml min
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. Electrophysiological responses were tested at room temperature (22 ± 248C) only in those cells that were phase dense.
Whole-cell patch-clamp recording
Conventional (Hamill et al., 1981) and amphotericin Bperforated (Rae et al., 1991) whole-cell patch-clamp methods were employed to voltage-clamp smooth muscle cells. Recording electrodes were pulled from borosilicate glass capillaries (WPI, Berlin, Germany) and ®re-polished to create a pipette resistance of 2 ± 5 MO when ®lled with internal solution. A low-noise, high-performance Axopatch 200B (Axon Instruments, U.S.A.) patch-clamp ampli®er driven by an IBM computer in conjunction with an A/D, D/A board (DigiData 1200 A/B series interface, Axon Instruments, U.S.A.) was used to generate and apply voltage pulses to the clamped cells and record the corresponding membrane currents. Current signals, after compensation for whole-cell capacitance, series resistance and liquid junction potential, were low-pass ®ltered at 1 kHz and digitized at 3 kHz prior to being stored on the computer hard disk. I Ca(L) was always recorded in 5 mM Ca 2+ -containing PSS: this concentration was shown to cause maximal peak current in arterial smooth muscle cells (Bolton et al., 1988) .
I Ca(L) was measured over a range of test potentials (250 ms) from 750 to 50 mV from a holding potential (V h ) of 750 mV. Data were collected once the current amplitude had been stabilized (usually 5 ± 10 min after the whole-cell con®guration had been obtained). I Ca(L) did not run down during the following 30 ± 40 min under these conditions. Steady-state inactivation curves, recorded twice from the same cell (in the absence and presence of the drug, respectively), were obtained using the double-pulse protocol. Once various levels of the conditioning potential had been applied for 5 s, followed by a short (5 ms) return to the V h , a test pulse (250 ms) to 10 mV was delivered to evoke the current. Under control conditions, the 50% inactivation potentials evaluated by Boltzmann ®tting of the ®rst curve (723.20+0.27 mV, n=3) was not signi®cantly dierent from that of the second curve recorded after 10 min (723.96+0.37 mV).
Activation curves were derived from the current-voltage relationships (see Figure 1b) . Conductance (G) was calculated from the equation G=I Ca /(E m 7E Ca ), where I Ca is the peak current elicited by depolarizing test pulses to the various potentials and E Ca is the equilibrium potential. G max is the maximal Ca 2+ conductance (calculated at potentials above 10 mV). The points for G/G max were plotted against the membrane potential as relative amplitude.
To examine the use-dependent inhibition of I Ca(L) , a train of test pulses (10 mV from a V h of 750 or 780 mV for 50 ms) was applied at dierent pulse intervals, ranging from 1 to 5 s (1, 0.5, 0.33 and 0.2 Hz) before and after bath application of the drug. K + currents were blocked with 30 mM tetraethylammonium (TEA) in the PSS and Cs + in the internal solution. Values were corrected for leakage using the P/4 protocol or 300 mM Cd 2+ which was assumed to completely block I Ca(L) .
Solutions and chemicals
Ca 2+ -free PSS contained (in mM): NaCl 110, KCl 5.6, HEPES 10, taurine 20, glucose 20, MgCl 2 1.2, Na-pyruvate 5 (pH 7.4). The 5 mM Ca 2+ -containing PSS was prepared by replacing NaCl with equimolar CaCl 2 .
The internal solution for the conventional method (pCa 8.4) consisted of (in mM): CsCl 100, HEPES 10, EGTA 11, MgCl 2 2, CaCl 2 1, Na-pyruvate 5, succinic acid 5, oxalacetic acid 5, Na 2 ATP 3 and phosphocreatine 5, pH was adjusted to 7.4 with CsOH. For the perforated method, the internal solution (pCa 8.4) contained (in mM): CsCl 125, HEPES 10, EGTA 11, MgCl 2 2, CaCl 2 1, amphotericin B (200 mg/ml), pH was adjusted to 7.4 with CsOH.
Amphotericin B (100 mg/ml) was ®rst dissolved in dimethylsulphoxide and then added to the internal solution.
The osmolarity of PSS was adjusted to 335 mosmol and that of the internal solution to 310 mosmol (Stansfeld & Mathie, 1993) by means of an osmometer (Osmostat OM 6020, Menarini Diagnostics, Italy).
The chemicals used were: collagenase (type XI), TEA, bovine serum albumin, trypsin inhibitor, amphotericin B and CdCl 2 (Sigma Chimica, Italy). Norbormide was a kind gift of I.N.D.I.A. S.p.a. (Padova, Italy). Norbormide dissolved directly in dimethylformamide, was diluted at least 1000 times in PSS, prior to use. The resulting concentrations of dimethylformamide (below 0.1%) failed to alter the current (data not shown). Final drug concentrations are presented in the text.
Following control measurements, each cell was exposed to drug by perfusing the experimental chamber with a drugcontaining PSS.
Statistical analysis
Acquisition and analysis of data were accomplished using pClamp 8.0.1.12 software (Axon Instruments, U.S.A.) and GraphPad Prism version 3.02 (GraphPad Software, U.S.A.). Data are reported as mean+s.e.mean; n is the number of animals (indicated in parentheses). Statistical analyses and signi®cance as measured by the Student's t test for unpaired and paired samples, as appropriate, were obtained using GraphPad InStat version 3.02 (GraphPad Software, U.S.A.). In all comparisons, P50.05 was considered signi®cant.
The current-voltage relationships were calculated on the basis of the peak values from the original currents.
Results
Inhibitory action of norbormide on I Ca(L)
The mean membrane capacitance of caudal artery smooth muscle cells was 54.3+1.6 pF (n=46) and was not aected by application of norbormide. Figure 1 shows the eect of norbormide on I Ca(L) . Norbormide (50 mM) signi®cantly inhibited the peak inward current at all potentials tested; this inhibition, however, was not accompanied by a signi®cant shift of the currentvoltage curve along the voltage axis. Furthermore, norbormide inhibited I Ca(L) in a concentration-dependent manner. Figure 1d shows the time course of the eects of norbormide on the current. After I Ca(L) had reached steady values, 50 mM norbormide was added to the bath solution. This produced a gradual decrease of the current (over 5 min) that was reversible upon wash-out. A close correlation was found between maximal inhibition of I Ca(L) by 50 mM norbormide and both pulse frequency and V h . In fact, I Ca(L) decreased to 54.9+4.5% (n=6) and to 37.9+0.6% (n=3, P50.05) of control when test pulses were given, from V h of 750 mV, every 30 s (i.e. at 0.033 Hz) and every 3 s (0.33 Hz), respectively. Furthermore, at 0.033 Hz, norbormide inhibited I Ca(L) evoked from V h 780 mV to 75.0+5.5% (n=3, P50.05) of control. Effect of norbormide on steady-state inactivation and activation curves for I Ca(L)
The voltage dependence of norbormide inhibition was analysed by determining the steady-state inactivation curve of I Ca(L) . Norbormide (50 mM) signi®cantly shifted the steadystate inactivation curve to more negative potentials ( Figure  2a,b) . The 50% inactivation potentials evaluated by Boltzmann ®tting were 722.71+1.39 mV (control, n=6) and 738.26+3.56 mV (norbormide, n=6, P50.01, Student's t test for paired samples). Also the slope factor (77.04+0.79 mV, control) was signi®cantly decreased by norbormide (78.69+0.96 mV, P50.05). Noticeably, the blockade of I Ca(L) by norbormide was still evident even at negative conditioning potentials. In fact, after conditioning pulses to 780 mV for 5 s, I Ca(L) was still reduced to 59.6+4.9% by 50 mM norbormide (Figure 2b ).
Activation curves, obtained from the current ± voltage relationships of Figure 1b and ®tted to the Boltzmann equation, are shown in Figure 2a . The 50% activation potential as well as the slope factor obtained from individual experiments (0.99+0.54 and 8.15+0.48 mV, control, n=5) were not aected by 50 mM norbormide (2.45+0.78 and 7.31+0.37 mV, n=4).
Effect of norbormide on I Ca(L) activation and inactivation rates
The eect of norbormide on the kinetic of I Ca(L) activation and inactivation was analysed. Activation and inactivation rates were measured under control conditions as well as at the plateau of norbormide inhibition. The current evoked at 10 mV from V h 750 mV activates and then declined with time courses that could be ®tted by mono-exponential equations, with a t of activation of 1.72+0.11 ms and a t of inactivation of 74.34+6.57 ms (n=6) (Figure 2c ). The addition to the perfusion medium of 50 mM norbormide had no eects on both activation and inactivation rates (t of activation of 1.88+0.21 ms and t of inactivation of 74.21+4.26 ms, n=6).
Use-dependent blockage of I Ca(L) by norbormide
To examine the possible use-dependent inhibition of I Ca(L) by norbormide, a train of test pulses (750 to 10 mV for 50 ms) was applied at dierent pulse intervals, ranging from 1 to 5 s (namely 1, 0.5, 0.33 and 0.2 Hz) (Figure 3 ). In the absence of norbormide, I Ca(L) remained stable at 0.2 and 0.33 Hz whereas a progressive inhibition of the current amplitude during repetitive stimulation was observed at 0.5 and 1 Hz. With 50 mM norbormide, the current inhibition showed an accumulation during the repetitive stimulations at all frequencies, the higher frequency causing the greater inhibition. The use-dependent block, evaluated with the current amplitude evoked by the 20th applied stimulus was signi®cantly lower than that observed under the corresponding control condition.
The use-dependent block of I Ca(L) by norbormide depended upon the V h applied. In fact, I Ca(L) evoked at 0.5 Hz from V h of 750 mV was reduced to 57.6+2.2% of control (n=5) whereas that from V h of 780 mV to 78.6+2.9% (n=4, P50.001, Student's t test for unpaired samples).
Contractile effect of norbormide with conventional and perforated method
The contractile eect of norbormide was evaluated by recording the morphological changes of the cells (shortening with formation of membranous evaginations; see Ives et al., 1978) with conventional as well as perforated method. As shown in Figure 4 , the addition of 50 mM norbormide caused the contraction of the cells impaled only with the perforated Figure 2 The eects of norbormide on both the activation and inactivation curves, and I Ca(L) activation and inactivation kinetics. (a,b) Steady-state inactivation curves, obtained in the absence (control) and presence of 50 mM norbormide (NRB), were ®tted to the Boltzmann equation. Peak current values were used. The steadystate inactivation curve was obtained using the double-pulse protocol (see Methods section). The current measured during the test pulse is plotted against membrane potential and expressed as relative amplitude (a) and in per cent of control (b). Activation curves were obtained from the current ± voltage relationships of Figure 1b and ®tted to the Boltzmann equation (see Methods section). Relative amplitude is plotted against membrane potential. Each point represents the mean+s.e.mean of six cells (n=5). (c) Average traces measured from six cells (n=6) of conventional whole-cell I Ca(L) in rat tail artery myocytes elicited with 250 ms clamp pulses to 10 mV from a V h of 750 mV, measured in the absence (control, black) or presence of 50 mM norbormide (grey). The drug trace is magni®ed (magni®cation is 1.84) so that the peak amplitudes of the traces before and after drug are matched. Vertical bar refers only to control trace.
method. This determined the loss of the seal thus preventing I Ca(L) from being recorded in the presence of the drug. Noticeably, with the conventional method, all the cells but those impaled (i.e. dialysed) contracted after the addition of norbormide.
Discussion
This study provides the ®rst electrophysiological evidence that norbormide is an inhibitor of vascular L-type Ca 2+ channels, as demonstrated by the concentration-dependent inhibitory eect elicited by the drug on I Ca(L) . This ®nding is in accordance with previous data obtained in cardiac tissues (Bova et al., 1997) and possibly accounts, at least in part, for the relaxant eect of the drug observed in rat aorta and in several non-rat arteries (Bova et al., 1996) . In fact, we can not rule out that norbormide myorelaxing activity originates from additional target sites since the 50% inhibition of I Ca(L) observed at 50 mM concentration does not correlate to the full relaxation of rat aorta obtained with the same concentration (see Bova et al., 1996) . Additional experiments on single cells isolated from vascular beds fully relaxed by norbormide are in progress in order to clarify this point.
The Ca 2+ entry blocker eect of norbormide in vascular myocytes shows electrophysiological features which are partially shared by other well known Ca 2+ channel inhibitors such as verapamil and nicardipine. In fact, norbormide, like verapamil (McDonald et al., 1994) , inhibited I Ca(L) in a frequency-dependent fashion (use-dependent block), i.e. the repetitive depolarization with high frequency potentiated inhibition of I Ca(L) ; also, norbormide, like nicardipine (Kuriyama et al., 1995) , shifted the voltage dependence of the inactivation curve to more negative potentials, i.e. the inhibition of I Ca(L) was more marked at a more depolarized holding potential. These eects indicate that norbormide stabilises Ca 2+ channels in their inactivated state (see Bean, 1984) and that norbormide Ca 2+ entry blocking eect is voltage-dependent, that is the extent of I Ca(L) inhibition is modi®ed by changes in membrane potential. Another feature of norbormide eect is that the blockade of I Ca(L) was only weakened but not abolished even at negative V h (Wegener et al., 2000) , indicating that the blocked channels can not be restored to the available pool by hyperpolarization that normally permits drug release from the weakly binding closed ± state (McDonald et al., 1994) ; this suggests that, in caudal artery myocytes, norbormide rapidly binds to the open/inactivated channel, preferentially stabilising it in the inactivated state.
The characteristics of norbormide Ca 2+ channel antagonism described here, such as the extent of inhibition, time for maximal eect development, depression of current-voltage relationship, use-dependency of the eect as well as the lack of eect on I Ca(L) activation and inactivation rates, looked similar to those observed previously in guinea-pig cardiac myocytes (Bova et al., 1997) . On the contrary, rat caudal artery myocytes displayed a reversibility of the inhibition upon wash-out that was only partially observed in cardiac myocytes. Norbormide caused a signi®cant decrease in the slope of the steady-state inactivation curve, thus indicating that the drug alters the sensitivity of the channel inactivation mechanism to membrane voltage. The same conclusion, however, can not be drawn for the voltage dependence of the channel activation, since norbormide did not modify the corresponding curve.
Strikingly enough, norbormide inhibits I Ca(L) in the same cells where it induces its selective contractile eect (Bova et al., 1996; Figure 4, present manuscript) . This indicates that the drug is able to activate, in the same cell, both vasoconstriction and vasorelaxant mechanisms and that the selective myotonic eect of norbormide in the rat peripheral vessels originates from its interaction with a target, beyond the L-type Ca 2+ channel, which hierarchically prevails over the decrease in the Ca 2+ in¯ux to be expected from I Ca(L) Figure 3 Use-dependent inhibition of I Ca(L) by norbormide. The peak current amplitude of I Ca(L) was measured during repetitive stimulation at intervals (Dt) of 5, 3, 2 and 1 s (0.2, 0.33, 0.5 and 1 Hz, respectively), before (control, open symbols) and 5 min after bath application of 50 mM norbormide (NRB, closed symbols). The peak current amplitudes were normalized to that induced by the ®rst step pulse. *P50.05, ***P50.001 (Student's t-test for unpaired samples) refers to the 20th pulse. Data points are mean+s.e.mean of 4 ± 5 cells (n=4). inhibition. This idea is further supported by the observation that norbormide causes contraction, but not relaxation, also in caudal artery rings depolarized with high K + (Bova, unpublished observations), i.e. under experimental conditions similar to those represented by voltage-clamp pulses of depolarization applied to evoke I Ca(L) . This second and hierarchically predominant target for norbormide action may be represented by PKC, since this enzyme, which plays a key role in the maintenance of tonic contraction of vascular smooth muscle (Rasmussen et al., 1987) , is activated by norbormide via a PLC pathway (Bova et al., 2001b) . The predominance of PKC-mediated events over Ca 2+ in¯ux via L-type Ca 2+ channels in the hierarchy of the mechanisms responsible for vascular smooth muscle tone has been recently observed also for quercetin, a natural polyphenolic avonoid, which, although activating I Ca(L) , induces vasorelaxation as a consequence of PKC inhibition (Saponara et al., 2002) . The involvement of distinct target sites in norbormide-induced eects in the rat caudal artery is also supported by the data obtained from amphotericin Bperforated cells (i.e. with minimal wash-out of the intracellular components), which demonstrated that an extensive dialysis of the cytoplasm (as in the case of the conventional method) prevented norbormide-induced cell contraction but not norbormide inhibition of I Ca(L) . This observation suggests that diusible intracellular factors are necessary in order that norbormide contracts vessels (Bova et al., 2001a,b) . On the other hand, norbormide inhibition of I Ca(L) seems to be related to a direct interaction of the drug with the channel protein, although the possible involvement, in this eect, of intracellular signalling pathways can not be ruled out.
The present electrophysiological data point to norbormide as a vascular Ca 2+ channel inhibitor characterized by a voltage-and use-dependent pro®le, strongly supporting the view of a Ca 2+ entry blocking agent endowed with a peculiar vasoconstrictor activity in rat terminal arteries. It is concluded that in rat caudal artery myocytes, at least two target sites are independently activated by norbormide: one, represented by L-type Ca 2+ channels, which is responsible for the Ca 2+ entry blocking eect; the other, presumably a membrane receptor, which causes a PKC-dependent activation of store-operated Ca 2+ channels, increase of Ca 2+ in¯ux and the ensuing contraction. The synthesis of novel norbormide derivatives would be very helpful to either foster a novel chemical class of Ca 2+ channel antagonists or identify a norbormide recognition site on the plasma membrane responsible for its selective vasocontracting action.
